Early Disturbed Placental Ischemia and Hypoxia Creates Immune Alteration and Vascular Disorder Causing Preeclampsia

Archives of Medical Research

Volumn 45, Issue 7, 2014, Pages 519-524

  Zárate, Arturo ^a   Saucedo, Renata ^a   Valencia, Jorge ^a   Manuel, Leticia ^a   Hernández, Marcelino ^a  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

Author keywords

Endothelial dysfunction; Hypertension; Placenta; Preeclampsia

Indexed keywords

AUTOANTIBODY; INTERLEUKIN 6; NITRIC OXIDE; PROSTACYCLIN; TUMOR NECROSIS FACTOR ALPHA; VASODILATOR AGENT; CYTOKINE; IL6 PROTEIN, HUMAN; PROSTACYCLIN DERIVATIVE;

ARTERIAL PRESSURE; BLOOD FLOW; ENDOTHELIAL DYSFUNCTION; HUMAN; HYPERTENSION; HYPOXIA; IMMUNOCOMPETENT CELL; MULTIPLE ORGAN FAILURE; PATHOPHYSIOLOGY; PLACENTA CIRCULATION; PLACENTA DISORDER; PLACENTA ISCHEMIA; PLACENTA PERFUSION; PREECLAMPSIA; REPRODUCTION; REVIEW; VASCULAR DISEASE; ANGIOGENESIS; ANOXIA; BLOOD; BLOOD PRESSURE; COMPLICATION; FEMALE; IMMUNOLOGY; INFLAMMATION; ISCHEMIA; METABOLISM; PHYSIOLOGY; PLACENTA; PRE-ECLAMPSIA; PREGNANCY; SECRETION (PROCESS); VASCULARIZATION;

ANOXIA; AUTOANTIBODIES; BLOOD PRESSURE; CYTOKINES; FEMALE; HUMANS; INFLAMMATION; INTERLEUKIN-6; ISCHEMIA; NEOVASCULARIZATION, PHYSIOLOGIC; NITRIC OXIDE; PLACENTA; PRE-ECLAMPSIA; PREGNANCY; PROSTAGLANDINS I; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84915797203     PISSN: 01884409     EISSN: 18735487     Source Type: Journal    
DOI: 10.1016/j.arcmed.2014.10.003     Document Type: Review

References (55)

1. Khan K.S., Wojdyla D., Say L., et al. WHO analysis of causes of maternal death: a systematic review. Lancet 2006, 367:1066-1074.
2. Duley L. The global impact of pre-eclampsia and eclampsia. Semin Perinatol 2009, 33:130-137.
3. Ronsmans C., Graham W. Maternal mortality: who, when, where, and why. Lancet 2006, 368:1189-1200.
4. Steegers E., von Dadelszen P., Duvekot J., et al. Pre-eclampsia. Lancet 2010, 376:631-644.
5. Redman C.W., Sargent I.L. Latest advances in understanding preeclampsia. Science 2005, 308:1592-1594.
6. Pennington K.A., Schlitt J.M., Jackson D.L., et al. Preeclampsia: multiple approaches for a multifactorial disease. Dis Model Mech 2012, 5:9-18.
7. Lisonkova S., Joseph K.S. Incidence of preeclampsia: risk factors and outcomes associated with early- versus late-onset disease. Am J Obstet Gynecol 2013, 209:544.e1-544.e12.
8. Duckitt K., Harrington D. Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies. BMJ 2005, 330:565-572.
9. st century. Obstet Gynecol 2014, 124:763-770.
10. Poon L.C., Kametas N.A., Chelemen T., et al. Maternal risk factors for hypertensive disorders in pregnancy: a multivariate approach. J Hum Hypertens 2010, 24:104-110.
11. Song D., Shi Y. Immune system modifications and feto-maternal immune tolerance. Chin Med J 2014, 127:3171-3180.
12. Billington W.D. The immunological problem of pregnancy: 50 years with the hope of progress. A tribute to Peter Medawar. J Reprod Immunol 2003, 60:1-11.
13. Medawar P.B. Some immunological and endocrinological problems raised by evolution of viviparity invertebrates. Symp Soc Exp Biol 1953, 7:320-328.
14. Sargent I.L., Germain S.J., Sacks G.P., et al. Trophoblast deportation and the maternal inflammatory response in pre-eclampsia. J Reprod Immunol 2003, 59:153-160.
15. Pantham P., Askelund K.J., Chamley L.W. Trophoblast deportation. II: A review of the maternal consequences of trophoblast deportation. Placenta 2011, 32:724-731.
16. Borzychowski A.M., Sargent I.L., Redman C.W.G. Inflammation and pre-eclampsia. Semin Fetal Neonatal Med 2006, 11:309-316.
17. Huppertz B., Kingdom J., Caniggia I., et al. Hypoxia favours necrotic versus apoptotic shedding of placental syncytiotrophoblast into the maternal circulation. Placenta 2003, 24:181-190.
18. LaMarca B. The role of immune activation in contributing to vascular dysfunction and the pathophysiology of hypertension during preeclampsia. Minerva Ginecol 2010, 62:105-120.
19. Lam C., Lim K.H., Karumanchi S.A. Circulating angiogenic factors in the pathogenesis and prediction of preeclampsia. Hypertension 2005, 46:1077-1085.
20. Young B.C., Levine R.J., Karumanchi S.A. Pathogenesis of preeclampsia. Annu Rev Pathol 2010, 5:173-192.
21. Brett K.E., Ferraro Z.M., Yockell-Lelievre J., et al. Maternal-fetal nutrient transport in pregnancy: the role of placenta. Int J Mol Sci 2014, 15:16153-16185.
22. John R., Hemberger M. A placenta for life. Reprod Biomed Online 2012, 25:5-11.
23. Red K., Zhou Y., Genbacev O., et al. Trophoblast differentiation during embryo implantation and formation of the maternal-fetal interface. JClin Invest 2004, 114:744-754.
24. Cartwright J.E., Fraser R., Leslie K., et al. Remodelling at the maternal-fetal interface: relevance to human pregnancy disorders. Reproduction 2010, 140:803-813.
25. Lyall F. Mechanisms regulating cytotrophoblast invasion in normal pregnancy and pre-eclampsia. Aust N Z J Obstet Gynaecol 2006, 46:266-273.
26. Goldman Wohl D.S., Ariel I., Greenfield C., et al. Lack of human leukocyte antigen-G expression in extravillous trophoblasts is associated with pre-eclampsia. Mol Hum Reprod 2000, 6:88-95.
27. Szekeres J. Immunological relationship between the mother and the fetus. Int Rev Immunol 2002, 21:471-495.
28. Hiby S.E., Apps R., Sharkey A.M., et al. Maternal activating KIRs protect against human reproductive failure mediated by fetal HLA-C2. J Clin Invest 2010, 120:4102-4110.
29. Sargent I.L., Borzychowski A.M., Redman C.W.G. NK cells and human pregnancy-an inflammatory view. Trends Immunol 2006, 27:399-404.
30. Moffett A. Natural killer cells and pregnancy. Nat Rev Immunol 2002, 2:656-663.
31. Ouzounian J., Elkayam U. Physiologic changes during normal pregnancy and delivery. Cardiol Clin 2012, 30:317-329.
32. Verdonk K., Visser W., Van Der Meiracker A.H., et al. The rennin-angiotensin-aldosterone system in pre-eclampsia: the delicate balance between good and bad. Clin Sci 2014, 126:537-544.
33. Wang A., Rana S., Karumanchi S.A. Preeclampsia: the role of angiogenic factors in its pathogenesis. Physiology 2009, 24:147-168.
34. Gupta S., Agarwal A., Sharma R.K. The role of placental oxidative stress and lipid peroxidation in preeclampsia. Obstet Gynecol Surv 2005, 60:807-816.
35. Gilbert J.S., Ryan M.J., LaMarca B.B., et al. Pathophysiology of hypertension during preeclampsia: linking placental ischemia with endothelial dysfunction. Am J Physiol Heart Circ Physiol 2008, 294:541-550.
36. Manuel L., López R., Zárate A., et al. Leptin mediated ObRb receptor increases expression of adhesion intercellular molecules and cyclooxygenase 2 on murine aorta tissue inducing endothelial dysfunction. Int J Clin Exp Med 2013, 6:192-196.
37. Leung D.N., Smith S.C., To K.F., et al. Increased placental apoptosis in pregnancies complicated by preeclampsia. Am J Obstet Gynecol 2001, 184:1249-1250.
38. Laresgoiti E. A leading role for the immune system in the pathophysiology of preeclampsia. J Leukoc Biol 2013, 94:247-257.
39. Barakonyi A., Miko E., Szereday L., et al. Cell death mechanisms and potentially cytotoxic natural immune cells in human pregnancies complicated by preeclampsia. Reprod Sci 2014, 21:155-166.
40. Smárason A.K., Gunnarsson A., Alfredsson J.H., et al. Monocytosis and monocytic infiltration of decidua in early pregnancy. J Clin Lab Immunol 1986, 21:1-5.
41. Sacks G.P., Redman C.W., Sargent I.L. Monocytes are primed to produce the Th1 type cytokine IL-12 in normal human pregnancy: an intracellular flow cytometric analysis of peripheral blood mononuclear cells. Clin Exp Immunol 2003, 131:490-497.
42. Koumandakis E., Koumandaki I., Kaklamani E., et al. Enhanced phagocytosis of mononuclear phagocytes in pregnancy. Br J Obstet Gynaecol 1986, 93:1150-1154.
43. Saucedo R., Zarate A., Basurto L., et al. Relationship between circulating adipokines and insulin resistance during pregnancy and postpartum in women with gestational diabetes. Arch Med Res 2011, 42:318-323.
44. Matthiesen L., Berg G., Ernerudh J., et al. Immunology of preeclampsia. Chem Immunol Allergy 2005, 89:49-61.
45. Bazavilvaso M.A., Hernández M., Santillán J.G., et al. Oxidative stress changes in pregnant patients with and without severe preeclampsia. Arch Med Res 2011, 42:195-198.
46. Pober J.S., Sessa W.C. Evolving functions of endothelial cells in inflammation. Nature Rev Immunol 2007, 7:803-815.
47. Anim-Nyame N., Gamble J., Sooranna S.R., et al. Microvascular permeability is related to circulating levels of tumour necrosis factor-in pre-eclampsia. Cardiovasc Res 2003, 58:162-169.
48. Triggle C., Mathews S., Ravishankar S., et al. The endothelium: influencing vascular smooth muscle in many ways. Can J Physiol Pharmacol 2012, 90:713-738.
49. Henderson J.T., Whitlock E.P., O'Connor E., et al. Low-dose aspirin for prevention of morbidity and mortality from preeclampsia: a systematic evidence review for the U.S. preventive services task force. Ann Intern Med 2014, 160:695-703.
50. Henessy A., Pilmore H.L., Simmons L.A., et al. A deficiency of placental IL-10 in preeclampsia. J Immunol 1999, 163:3491-3495.
51. Levine R.J., Maynard S.E., Qian C., et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004, 350:672-683.
52. Ahmad S., Ahmed A. Elevated placental soluble vascular endothelial growth factor receptor-1 inhibits angiogenesis in preeclampsia. Circ Res 2004, 95:884-891.
53. Levine R.J., Lam C., Qian C., et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006, 355:992-1005.
54. Hertig A., Berkane N., Lefevre G., et al. Maternal serum sFlt1 concentration is an early and reliable predictive marker of preeclampsia. Clin Chem 2004, 50:1702-1703.
55. Maynard S.E., Min J.Y., Merchan J., et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dys-function, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003, 111:649-658.